Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Maxim Group to hold a virtual conference » 04:55
03/18/21
03/18
04:55
03/18/21
04:55
CNSP

CNS Pharmaceuticals

$2.85 /

+0.18 (+6.74%)

, KTRA

Kintara Therapeutics

$2.14 /

-0.02 (-0.93%)

, PSTV

Plus Therapeutics

$2.85 /

+0.08 (+2.89%)

, TCON

Tracon Pharmaceuticals

$9.30 /

+0.2 (+2.20%)

, MDNA

Medicenna Therapeutics

$4.01 /

-0.01 (-0.25%)

, INO

Inovio

$10.53 /

+0.07 (+0.67%)

, ONCR

Oncorus

$16.33 /

-0.485 (-2.88%)

, GOVX

GeoVax Labs

$5.73 /

+0.39 (+7.30%)

, HTBX

Heat Biologics

$8.66 /

+0.3 (+3.59%)

, SLS

Sellas Life Sciences

$11.67 /

+1.25 (+12.00%)

, PLSE

Pulse Biosciences

$25.60 /

-0.4 (-1.54%)

, SRTS

Sensus Healthcare

$4.39 /

-0.02 (-0.45%)

, VERO

Venus Concept

$2.77 /

+0.18 (+6.95%)

, SOLY

Soliton

$16.86 /

-0.67 (-3.82%)

, CLXPF

Cybin

$0.00 /

+ (+0.00%)

, MMED

Midas Medici

$0.00 /

+ (+0.00%)

, CHFS

CHF Solutions

$6.19 /

-1.15 (-15.67%)

, ECOR

electroCore

$2.19 /

+0.095 (+4.53%)

, BIOL

Biolase

$1.01 /

+0.0553 (+5.79%)

, AEMD

Aethlon Medical

$2.25 /

-0.06 (-2.60%)

, ZSAN

Zosano Pharma

$1.47 /

+0.14 (+10.53%)

, NLSP

NLS Pharmaceutics

$4.51 /

+0.15 (+3.44%)

, CYTH

Cyclo Therapeutics

$12.80 /

+0.41 (+3.31%)

, MNPR

Monopar Therapeutics

$7.38 /

-0.11 (-1.47%)

Inaugural Emerging Growth…

Inaugural Emerging Growth Virtual Conference 2021 will be held on March 17-19.

ShowHide Related Items >><<
ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

SOLY Soliton
$16.86 /

-0.67 (-3.82%)

SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

PSTV Plus Therapeutics
$2.85 /

+0.08 (+2.89%)

PLSE Pulse Biosciences
$25.60 /

-0.4 (-1.54%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

NLSP NLS Pharmaceutics
$4.51 /

+0.15 (+3.44%)

MNPR Monopar Therapeutics
$7.38 /

-0.11 (-1.47%)

MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

KTRA Kintara Therapeutics
$2.14 /

-0.02 (-0.93%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

GOVX GeoVax Labs
$5.73 /

+0.39 (+7.30%)

ECOR electroCore
$2.19 /

+0.095 (+4.53%)

CYTH Cyclo Therapeutics
$12.80 /

+0.41 (+3.31%)

CNSP CNS Pharmaceuticals
$2.85 /

+0.18 (+6.74%)

CHFS CHF Solutions
$6.19 /

-1.15 (-15.67%)

BIOL Biolase
$1.01 /

+0.0553 (+5.79%)

AEMD Aethlon Medical
$2.25 /

-0.06 (-2.60%)

CNSP CNS Pharmaceuticals
$2.85 /

+0.18 (+6.74%)

02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/24/20 Ladenburg
CNS Pharmaceuticals initiated with a Buy at Ladenburg
KTRA Kintara Therapeutics
$2.14 /

-0.02 (-0.93%)

09/14/20 Aegis
Kintara Therapeutics initiated with a Buy at Aegis
PSTV Plus Therapeutics
$2.85 /

+0.08 (+2.89%)

02/11/21
Fly Intel: Top five analyst initiations
02/11/21 H.C. Wainwright
Plus Therapeutics initiated with a Buy at H.C. Wainwright
01/25/21 Ladenburg
Plus Therapeutics initiated with a Buy at Ladenburg
10/16/20
Fly Intel: Top five analyst initiations
TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Maxim
Tracon Pharmaceuticals initiated with a Buy at Maxim
12/04/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $12 from $7 at H.C. Wainwright
09/17/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $7 from $4 at H.C. Wainwright
MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

12/17/20 Oppenheimer
Medicenna Therapeutics initiated with an Outperform at Oppenheimer
09/10/20 H.C. Wainwright
Medicenna Therapeutics initiated with a Buy at H.C. Wainwright
INO Inovio
$10.53 /

+0.07 (+0.67%)

03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
02/11/21 Oppenheimer
Inovio initiated with an Outperform at Oppenheimer
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

03/16/21
Fly Intel: Top five analyst initiations
03/16/21 Maxim
Oncorus initiated with a Buy at Maxim
11/11/20 Piper Sandler
Oncorus timelines remain on track after Q3 results, says Piper Sandler
10/27/20 Jefferies
Oncorus initiated with a Buy at Jefferies
GOVX GeoVax Labs
$5.73 /

+0.39 (+7.30%)

11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

03/02/21 Cantor Fitzgerald
Heat Biologics initiated with an Overweight at Cantor Fitzgerald
02/09/21 Alliance Global Partners
Heat Biologics price target raised to $40 from $5 at Alliance Global Partners
12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
PLSE Pulse Biosciences
$25.60 /

-0.4 (-1.54%)

03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
02/04/21 H.C. Wainwright
Pulse Biosciences price target raised to $46 from $40 at H.C. Wainwright
01/26/21 H.C. Wainwright
Pulse Biosciences price target raised to $40 from $16 at H.C. Wainwright
SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

03/01/21 H.C. Wainwright
Sensus Healthcare price target raised to $6 from $4 at H.C. Wainwright
02/26/21 Northland
Northland upgrades Sensus Healthcare to Outperform after 'strong' Q4 report
02/26/21 Northland
Sensus Healthcare upgraded to Outperform from Market Perform at Northland
12/16/20 Northland
Sensus Healthcare downgraded to Market Perform on valuation at Northland
VERO Venus Concept
$2.77 /

+0.18 (+6.95%)

12/29/20 BTIG
Venus Concept flying under the radar, says BTIG
12/08/20 Stifel
Venus Concept initiated with a Hold at Stifel
12/08/20 Stifel
Venus Concept initiated with a Hold at Stifel
11/16/20 Oppenheimer
Venus Concept upgraded to Outperform with $4 target at Oppenheimer
SOLY Soliton
$16.86 /

-0.67 (-3.82%)

03/08/21 Maxim
Soliton's multiple 2021 trials to expand its pipeline, says Maxim
02/08/21 Maxim
Soliton price target raised to $25 from $22 at Maxim
02/02/21 Cantor Fitzgerald
Soliton price target raised to $20 from $12 at Cantor Fitzgerald
07/15/20 Cantor Fitzgerald
Soliton initiated with an Overweight at Cantor Fitzgerald
CLXPF Cybin
$0.00 /

+ (+0.00%)

03/15/21 Canaccord
Cybin initiated with a Buy at Canaccord
01/14/21 Stifel
Cybin initiated with a Speculative Buy at Stifel
MMED Midas Medici
$0.00 /

+ (+0.00%)

CHFS CHF Solutions
$6.19 /

-1.15 (-15.67%)

10/21/20 Maxim
CHF Solutions price target lowered to $20 from $45 at Maxim
06/05/20 Maxim
CHF Solutions initiated with a Buy at Maxim
ECOR electroCore
$2.19 /

+0.095 (+4.53%)

10/22/20 Brookline
electroCore initiated with a Buy at Brookline
09/30/20
Fly Intel: Top five analyst initiationsNewPage
09/30/20 Maxim
electroCore initiated with a Buy at Maxim
09/30/20 Maxim
electroCore initiated with a Buy at Maxim
BIOL Biolase
$1.01 /

+0.0553 (+5.79%)

01/26/21 Maxim
Biolase price target raised to $2 at Maxim on 'strong' preliminary Q4 revenue
10/14/20 Maxim
Biolase initiated with a Buy at Maxim
04/09/20
Biolase supplying ventilators 'highly encouraging,' says Dougherty
AEMD Aethlon Medical
$2.25 /

-0.06 (-2.60%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Maxim
Aethlon Medical initiated with a Buy at Maxim
ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

03/15/21 Maxim
Zosano Pharma price target raised to $2.50 from $1.50 at Maxim
10/22/20 BTIG
Zosano Pharma price target lowered to $2 from $7 at BTIG
10/02/20 H.C. Wainwright
Zosano Pharma price target lowered to $2.50 from $4 at H.C. Wainwright
09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
NLSP NLS Pharmaceutics
$4.51 /

+0.15 (+3.44%)

03/12/21 Brookline
NLS Pharmaceutics initiated with a Buy at Brookline
03/03/21 Maxim
NLS Pharmaceutics initiated with a Buy at Maxim
CYTH Cyclo Therapeutics
$12.80 /

+0.41 (+3.31%)

02/10/21 Maxim
Cyclo Therapeutics price target raised to $25 from $12 at Maxim
12/17/20 Maxim
Cyclo Therapeutics initiated with a Buy at Maxim
MNPR Monopar Therapeutics
$7.38 /

-0.11 (-1.47%)

01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

VERO Venus Concept
$2.77 /

+0.18 (+6.95%)

TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

SRTS Sensus Healthcare
$4.39 /

-0.02 (-0.45%)

SOLY Soliton
$16.86 /

-0.67 (-3.82%)

SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

PSTV Plus Therapeutics
$2.85 /

+0.08 (+2.89%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

MNPR Monopar Therapeutics
$7.38 /

-0.11 (-1.47%)

MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

KTRA Kintara Therapeutics
$2.14 /

-0.02 (-0.93%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

ECOR electroCore
$2.19 /

+0.095 (+4.53%)

CHFS CHF Solutions
$6.19 /

-1.15 (-15.67%)

BIOL Biolase
$1.01 /

+0.0553 (+5.79%)

AEMD Aethlon Medical
$2.25 /

-0.06 (-2.60%)

  • 17
    Mar
  • 12
    Feb
  • 29
    Jan
  • 21
    Jan
  • 23
    Dec
  • 22
    Dec
  • 02
    Oct
  • 25
    Sep
  • 01
    Sep
  • 26
    Jun
SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

ZSAN Zosano Pharma
$1.47 /

+0.14 (+10.53%)

VERO Venus Concept
$2.77 /

+0.18 (+6.95%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

NLSP NLS Pharmaceutics
$4.51 /

+0.15 (+3.44%)

MDNA Medicenna Therapeutics
$4.01 /

-0.01 (-0.25%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

GOVX GeoVax Labs
$5.73 /

+0.39 (+7.30%)

TCON Tracon Pharmaceuticals
$9.30 /

+0.2 (+2.20%)

SLS Sellas Life Sciences
$11.67 /

+1.25 (+12.00%)

ONCR Oncorus
$16.33 /

-0.485 (-2.88%)

INO Inovio
$10.53 /

+0.07 (+0.67%)

HTBX Heat Biologics
$8.66 /

+0.3 (+3.59%)

Conference/Events
Maxim Group to hold a virtual conference » 09:48
03/17/21
03/17
09:48
03/17/21
09:48
CNSP

CNS Pharmaceuticals

$2.65 /

-0.02 (-0.75%)

, KTRA

Kintara Therapeutics

$2.08 /

-0.08 (-3.70%)

, PSTV

Plus Therapeutics

$2.75 /

-0.02 (-0.72%)

, TCON

Tracon Pharmaceuticals

$8.80 /

-0.3 (-3.30%)

, MDNA

Medicenna Therapeutics

$4.00 /

-0.02 (-0.50%)

, INO

Inovio

$10.33 /

-0.13 (-1.24%)

, ONCR

Oncorus

$16.50 /

-0.315 (-1.87%)

, GOVX

GeoVax Labs

$5.40 /

+0.06 (+1.12%)

, HTBX

Heat Biologics

$8.12 /

-0.24 (-2.87%)

, SLS

Sellas Life Sciences

$10.42 /

+ (+0.00%)

, PLSE

Pulse Biosciences

$26.20 /

+0.2 (+0.77%)

, SRTS

Sensus Healthcare

$4.40 /

-0.01 (-0.23%)

, VERO

Venus Concept

$2.43 /

-0.16 (-6.18%)

, SOLY

Soliton

$16.80 /

-0.73 (-4.16%)

, CLXPF

Cybin

$0.00 /

+ (+0.00%)

, MMED

Midas Medici

$0.00 /

+ (+0.00%)

, CHFS

CHF Solutions

$5.87 /

-1.47 (-20.03%)

, ECOR

electroCore

$2.07 /

-0.025 (-1.19%)

, BIOL

Biolase

$0.90 /

-0.0547 (-5.73%)

, AEMD

Aethlon Medical

$2.22 /

-0.09 (-3.90%)

, ZSAN

Zosano Pharma

$1.38 /

+0.05 (+3.76%)

, NLSP

NLS Pharmaceutics

$4.32 /

-0.04 (-0.92%)

, CYTH

Cyclo Therapeutics

$11.56 /

-0.83 (-6.70%)

, MNPR

Monopar Therapeutics

$7.40 /

-0.09 (-1.20%)

Inaugural Emerging Growth…

Inaugural Emerging Growth Virtual Conference 2021 will be held on March 17-19.

ShowHide Related Items >><<
ZSAN Zosano Pharma
$1.38 /

+0.05 (+3.76%)

TCON Tracon Pharmaceuticals
$8.80 /

-0.3 (-3.30%)

SRTS Sensus Healthcare
$4.40 /

-0.01 (-0.23%)

SOLY Soliton
$16.80 /

-0.73 (-4.16%)

SLS Sellas Life Sciences
$10.42 /

+ (+0.00%)

PSTV Plus Therapeutics
$2.75 /

-0.02 (-0.72%)

PLSE Pulse Biosciences
$26.20 /

+0.2 (+0.77%)

ONCR Oncorus
$16.50 /

-0.315 (-1.87%)

NLSP NLS Pharmaceutics
$4.32 /

-0.04 (-0.92%)

MNPR Monopar Therapeutics
$7.40 /

-0.09 (-1.20%)

MDNA Medicenna Therapeutics
$4.00 /

-0.02 (-0.50%)

KTRA Kintara Therapeutics
$2.08 /

-0.08 (-3.70%)

INO Inovio
$10.33 /

-0.13 (-1.24%)

HTBX Heat Biologics
$8.12 /

-0.24 (-2.87%)

GOVX GeoVax Labs
$5.40 /

+0.06 (+1.12%)

ECOR electroCore
$2.07 /

-0.025 (-1.19%)

CYTH Cyclo Therapeutics
$11.56 /

-0.83 (-6.70%)

CNSP CNS Pharmaceuticals
$2.65 /

-0.02 (-0.75%)

CHFS CHF Solutions
$5.87 /

-1.47 (-20.03%)

BIOL Biolase
$0.90 /

-0.0547 (-5.73%)

AEMD Aethlon Medical
$2.22 /

-0.09 (-3.90%)

CNSP CNS Pharmaceuticals
$2.65 /

-0.02 (-0.75%)

02/02/21 Brookline
CNS Pharmaceuticals initiated with a Buy at Brookline
12/28/20
Fly Intel: Top five analyst calls
12/28/20 Ladenburg
CNS Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/24/20 Ladenburg
CNS Pharmaceuticals initiated with a Buy at Ladenburg
KTRA Kintara Therapeutics
$2.08 /

-0.08 (-3.70%)

09/14/20 Aegis
Kintara Therapeutics initiated with a Buy at Aegis
PSTV Plus Therapeutics
$2.75 /

-0.02 (-0.72%)

02/11/21
Fly Intel: Top five analyst initiations
02/11/21 H.C. Wainwright
Plus Therapeutics initiated with a Buy at H.C. Wainwright
01/25/21 Ladenburg
Plus Therapeutics initiated with a Buy at Ladenburg
10/16/20
Fly Intel: Top five analyst initiations
TCON Tracon Pharmaceuticals
$8.80 /

-0.3 (-3.30%)

02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Maxim
Tracon Pharmaceuticals initiated with a Buy at Maxim
12/04/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $12 from $7 at H.C. Wainwright
09/17/20 H.C. Wainwright
Tracon Pharmaceuticals price target raised to $7 from $4 at H.C. Wainwright
MDNA Medicenna Therapeutics
$4.00 /

-0.02 (-0.50%)

12/17/20 Oppenheimer
Medicenna Therapeutics initiated with an Outperform at Oppenheimer
09/10/20 H.C. Wainwright
Medicenna Therapeutics initiated with a Buy at H.C. Wainwright
INO Inovio
$10.33 /

-0.13 (-1.24%)

03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
02/11/21 Oppenheimer
Inovio initiated with an Outperform at Oppenheimer
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
ONCR Oncorus
$16.50 /

-0.315 (-1.87%)

03/16/21
Fly Intel: Top five analyst initiations
03/16/21 Maxim
Oncorus initiated with a Buy at Maxim
11/11/20 Piper Sandler
Oncorus timelines remain on track after Q3 results, says Piper Sandler
10/27/20 Jefferies
Oncorus initiated with a Buy at Jefferies
GOVX GeoVax Labs
$5.40 /

+0.06 (+1.12%)

11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
HTBX Heat Biologics
$8.12 /

-0.24 (-2.87%)

03/02/21 Cantor Fitzgerald
Heat Biologics initiated with an Overweight at Cantor Fitzgerald
02/09/21 Alliance Global Partners
Heat Biologics price target raised to $40 from $5 at Alliance Global Partners
12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
SLS Sellas Life Sciences
$10.42 /

+ (+0.00%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
PLSE Pulse Biosciences
$26.20 /

+0.2 (+0.77%)

03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
03/11/21 Maxim
Pulse Biosciences initiated with a Buy at Maxim
02/04/21 H.C. Wainwright
Pulse Biosciences price target raised to $46 from $40 at H.C. Wainwright
01/26/21 H.C. Wainwright
Pulse Biosciences price target raised to $40 from $16 at H.C. Wainwright
SRTS Sensus Healthcare
$4.40 /

-0.01 (-0.23%)

03/01/21 H.C. Wainwright
Sensus Healthcare price target raised to $6 from $4 at H.C. Wainwright
02/26/21 Northland
Northland upgrades Sensus Healthcare to Outperform after 'strong' Q4 report
02/26/21 Northland
Sensus Healthcare upgraded to Outperform from Market Perform at Northland
12/16/20 Northland
Sensus Healthcare downgraded to Market Perform on valuation at Northland
VERO Venus Concept
$2.43 /

-0.16 (-6.18%)

12/29/20 BTIG
Venus Concept flying under the radar, says BTIG
12/08/20 Stifel
Venus Concept initiated with a Hold at Stifel
12/08/20 Stifel
Venus Concept initiated with a Hold at Stifel
11/16/20 Oppenheimer
Venus Concept upgraded to Outperform with $4 target at Oppenheimer
SOLY Soliton
$16.80 /

-0.73 (-4.16%)

03/08/21 Maxim
Soliton's multiple 2021 trials to expand its pipeline, says Maxim
02/08/21 Maxim
Soliton price target raised to $25 from $22 at Maxim
02/02/21 Cantor Fitzgerald
Soliton price target raised to $20 from $12 at Cantor Fitzgerald
07/15/20 Cantor Fitzgerald
Soliton initiated with an Overweight at Cantor Fitzgerald
CLXPF Cybin
$0.00 /

+ (+0.00%)

03/15/21 Canaccord
Cybin initiated with a Buy at Canaccord
01/14/21 Stifel
Cybin initiated with a Speculative Buy at Stifel
MMED Midas Medici
$0.00 /

+ (+0.00%)

CHFS CHF Solutions
$5.87 /

-1.47 (-20.03%)

10/21/20 Maxim
CHF Solutions price target lowered to $20 from $45 at Maxim
06/05/20 Maxim
CHF Solutions initiated with a Buy at Maxim
ECOR electroCore
$2.07 /

-0.025 (-1.19%)

10/22/20 Brookline
electroCore initiated with a Buy at Brookline
09/30/20
Fly Intel: Top five analyst initiationsNewPage
09/30/20 Maxim
electroCore initiated with a Buy at Maxim
09/30/20 Maxim
electroCore initiated with a Buy at Maxim
BIOL Biolase
$0.90 /

-0.0547 (-5.73%)

01/26/21 Maxim
Biolase price target raised to $2 at Maxim on 'strong' preliminary Q4 revenue
10/14/20 Maxim
Biolase initiated with a Buy at Maxim
04/09/20
Biolase supplying ventilators 'highly encouraging,' says Dougherty
AEMD Aethlon Medical
$2.22 /

-0.09 (-3.90%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Maxim
Aethlon Medical initiated with a Buy at Maxim
ZSAN Zosano Pharma
$1.38 /

+0.05 (+3.76%)

03/15/21 Maxim
Zosano Pharma price target raised to $2.50 from $1.50 at Maxim
10/22/20 BTIG
Zosano Pharma price target lowered to $2 from $7 at BTIG
10/02/20 H.C. Wainwright
Zosano Pharma price target lowered to $2.50 from $4 at H.C. Wainwright
09/14/20 BTIG
Satsuma setback a positive for Zosano Pharma, says BTIG
NLSP NLS Pharmaceutics
$4.32 /

-0.04 (-0.92%)

03/12/21 Brookline
NLS Pharmaceutics initiated with a Buy at Brookline
03/03/21 Maxim
NLS Pharmaceutics initiated with a Buy at Maxim
CYTH Cyclo Therapeutics
$11.56 /

-0.83 (-6.70%)

02/10/21 Maxim
Cyclo Therapeutics price target raised to $25 from $12 at Maxim
12/17/20 Maxim
Cyclo Therapeutics initiated with a Buy at Maxim
MNPR Monopar Therapeutics
$7.40 /

-0.09 (-1.20%)

01/28/21 Roth Capital
Monopar Therapeutics initiated with a Buy at Roth Capital
09/24/20 Maxim
Monopar Therapeutics initiated with a Buy at Maxim
06/16/20 JonesTrading
JonesTrading backs Buy on Monoper after NorthStar Medical collaboration
ZSAN Zosano Pharma
$1.38 /

+0.05 (+3.76%)

VERO Venus Concept
$2.43 /

-0.16 (-6.18%)

TCON Tracon Pharmaceuticals
$8.80 /

-0.3 (-3.30%)

SRTS Sensus Healthcare
$4.40 /

-0.01 (-0.23%)

SOLY Soliton
$16.80 /

-0.73 (-4.16%)

SLS Sellas Life Sciences
$10.42 /

+ (+0.00%)

PSTV Plus Therapeutics
$2.75 /

-0.02 (-0.72%)

ONCR Oncorus
$16.50 /

-0.315 (-1.87%)

MNPR Monopar Therapeutics
$7.40 /

-0.09 (-1.20%)

MDNA Medicenna Therapeutics
$4.00 /

-0.02 (-0.50%)

KTRA Kintara Therapeutics
$2.08 /

-0.08 (-3.70%)

INO Inovio
$10.33 /

-0.13 (-1.24%)

HTBX Heat Biologics
$8.12 /

-0.24 (-2.87%)

ECOR electroCore
$2.07 /

-0.025 (-1.19%)

CHFS CHF Solutions
$5.87 /

-1.47 (-20.03%)

BIOL Biolase
$0.90 /

-0.0547 (-5.73%)

AEMD Aethlon Medical
$2.22 /

-0.09 (-3.90%)

  • 17
    Mar
  • 12
    Feb
  • 29
    Jan
  • 21
    Jan
  • 23
    Dec
  • 22
    Dec
  • 02
    Oct
  • 25
    Sep
  • 01
    Sep
  • 26
    Jun
SLS Sellas Life Sciences
$10.42 /

+ (+0.00%)

INO Inovio
$10.33 /

-0.13 (-1.24%)

ZSAN Zosano Pharma
$1.38 /

+0.05 (+3.76%)

VERO Venus Concept
$2.43 /

-0.16 (-6.18%)

ONCR Oncorus
$16.50 /

-0.315 (-1.87%)

NLSP NLS Pharmaceutics
$4.32 /

-0.04 (-0.92%)

MDNA Medicenna Therapeutics
$4.00 /

-0.02 (-0.50%)

INO Inovio
$10.33 /

-0.13 (-1.24%)

HTBX Heat Biologics
$8.12 /

-0.24 (-2.87%)

GOVX GeoVax Labs
$5.40 /

+0.06 (+1.12%)

TCON Tracon Pharmaceuticals
$8.80 /

-0.3 (-3.30%)

SLS Sellas Life Sciences
$10.42 /

+ (+0.00%)

ONCR Oncorus
$16.50 /

-0.315 (-1.87%)

INO Inovio
$10.33 /

-0.13 (-1.24%)

HTBX Heat Biologics
$8.12 /

-0.24 (-2.87%)

Over a month ago
Initiation
Heat Biologics initiated with an Overweight at Cantor Fitzgerald » 16:07
03/02/21
03/02
16:07
03/02/21
16:07
HTBX

Heat Biologics

$7.82 /

-0.35 (-4.28%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Heat Biologics with an Overweight rating and $22 price target. Recent positive data in the company's lead program, HS-110, highlight the strength of the company's proprietary immunotherapy platforms, said Kluska, who believes that "investors have yet to fully appreciate the potential utility of both this dataset and the versatility that Heat's platforms." Given where the stock is currently trading, she sees "significant upside" for HS-110 in NSCLC alone, but she also sees potential for expanded applications across solid tumors and COVID-19 for the company's other assets, the analyst added.

ShowHide Related Items >><<
HTBX Heat Biologics
$7.82 /

-0.35 (-4.28%)

HTBX Heat Biologics
$7.82 /

-0.35 (-4.28%)

02/09/21 Alliance Global Partners
Heat Biologics price target raised to $40 from $5 at Alliance Global Partners
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
10/14/20
Fly Intel: Top five analyst initiations
HTBX Heat Biologics
$7.82 /

-0.35 (-4.28%)

HTBX Heat Biologics
$7.82 /

-0.35 (-4.28%)

HTBX Heat Biologics
$7.82 /

-0.35 (-4.28%)

Recommendations
Heat Biologics price target raised to $40 from $5 at Alliance Global Partners » 15:06
02/09/21
02/09
15:06
02/09/21
15:06
HTBX

Heat Biologics

$11.73 /

+3.34 (+39.81%)

Alliance Global Partners…

Alliance Global Partners analyst James Molloy raised the firm's price target on Heat Biologics to $40 from $5 and keeps a Buy rating on the shares. The analyst notes that the company released positive data from its Phase 2 HS-110 study for patients with advanced non-small cell lung cancer in combination with Opdivo. This data builds upon the positive interim data Heat Biologics had previously released 2019 and Molloy believes augers well for the continued advancement of HS-110 in NSCLC patients in Phase 3 trials. Further, he thinks this preliminary data places Heat Biologics in a strong position to bring HS-110 to Phase 3 clinical trials in the second half of 2021 and helps validate the drug candidate's potential.

ShowHide Related Items >><<
HTBX Heat Biologics
$11.73 /

+3.34 (+39.81%)

HTBX Heat Biologics
$11.73 /

+3.34 (+39.81%)

02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
10/14/20
Fly Intel: Top five analyst initiations
10/14/20 B. Riley
B. Riley sees 200% upside in 'value vaccine play' Heat Biologics
HTBX Heat Biologics
$11.73 /

+3.34 (+39.81%)

HTBX Heat Biologics
$11.73 /

+3.34 (+39.81%)

HTBX Heat Biologics
$11.73 /

+3.34 (+39.81%)

HTBX Heat Biologics
$11.73 /

+3.34 (+39.81%)

Recommendations
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim » 10:52
02/09/21
02/09
10:52
02/09/21
10:52
HTBX

Heat Biologics

$13.88 /

+5.49 (+65.44%)

, SLS

Sellas Life Sciences

$10.00 /

-0.09 (-0.89%)

, INO

Inovio

$13.69 /

-0.17 (-1.23%)

Heat Biologics (HTBX)…

Heat Biologics (HTBX) shares are up 60% this morning on positive interim survival data from the company's ongoing Phase 2 trial of HS-110 and nivolumab in both previously treated checkpoint inhibitor-naive and CI-treated advanced non-small cell lung cancer patients, Maxim analyst Jason McCarthy tells investors in a research note. One-year survival rate for Cohort A was 61.7%, which compares favorably to the 50.7% one-year survival rate noted with single-agent nivolumab therapy in the CheckMate 057 study, says the analyst. McCarthy adds that while a lot of focus has recently been placed on Heat's Covid vaccine candidate, the company's core oncology programs are continuing to make progress. With checkpoints, the cancer vaccine discussion "is back on the table," and "there is value to be unlocked," predicts McCarthy. He lists Heat Biologics, Sellas Life Sciences (SLS) and Inovio (INO) as cancer vaccine plays. McCarthy keeps a Buy rating on Heat Biologics with a $22 price target.

ShowHide Related Items >><<
SLS Sellas Life Sciences
$10.00 /

-0.09 (-0.89%)

INO Inovio
$13.69 /

-0.17 (-1.23%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
10/14/20
Fly Intel: Top five analyst initiations
10/14/20 B. Riley
B. Riley sees 200% upside in 'value vaccine play' Heat Biologics
10/14/20 B. Riley
Heat Biologics initiated with a Buy at B. Riley Securities
SLS Sellas Life Sciences
$10.00 /

-0.09 (-0.89%)

12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
INO Inovio
$13.69 /

-0.17 (-1.23%)

01/08/21 Benchmark
Inovio price target lowered to $15 from $25 at Benchmark
12/28/20 Cantor Fitzgerald
Inovio may have viable third-generation vaccine, says Cantor Fitzgerald
12/28/20 H.C. Wainwright
Inovio Phase I Covid vaccine results 'very promising,' says H.C. Wainwright
12/24/20 Piper Sandler
Piper calls Inovio's COVID vaccine candidate 'an also-ran' after data published
SLS Sellas Life Sciences
$10.00 /

-0.09 (-0.89%)

INO Inovio
$13.69 /

-0.17 (-1.23%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

  • 21
    Jan
SLS Sellas Life Sciences
$10.00 /

-0.09 (-0.89%)

INO Inovio
$13.69 /

-0.17 (-1.23%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

INO Inovio
$13.69 /

-0.17 (-1.23%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

SLS Sellas Life Sciences
$10.00 /

-0.09 (-0.89%)

INO Inovio
$13.69 /

-0.17 (-1.23%)

HTBX Heat Biologics
$13.88 /

+5.49 (+65.44%)

On The Fly
Fly Intel: Pre-market Movers » 09:08
02/09/21
02/09
09:08
02/09/21
09:08
KALV

KalVista

$15.62 /

+0.41 (+2.70%)

, TLRY

Tilray

$30.21 /

+4.51 (+17.55%)

, HTBX

Heat Biologics

$8.37 /

+0.88 (+11.75%)

, SPGI

S&P Global

$325.31 /

+1.315 (+0.41%)

, INCY

Incyte

$93.55 /

+3.27 (+3.62%)

, ARMK

Aramark

$37.02 /

+0.39 (+1.06%)

, IIVI

II-VI

$88.69 /

+0.7 (+0.80%)

, HBI

Hanesbrands

$15.97 /

+0.11 (+0.69%)

, CNC

Centene

$58.27 /

-0.525 (-0.89%)

, COTY

Coty

$7.95 /

+0.305 (+3.99%)

, TTWO

Take-Two

$213.30 /

+5.925 (+2.86%)

, EKSO

Ekso Bionics

$13.04 /

+2.59 (+24.78%)

, CLF

Cleveland-Cliffs

$17.33 /

+0.65 (+3.90%)

, FIS

FIS

$133.39 /

+1.2 (+0.91%)

, BMY

Bristol-Myers

$60.24 /

-0.67 (-1.10%)

, GLUU

Glu Mobile

$9.38 /

+0.19 (+2.07%)

, EA

Electronic Arts

$142.49 /

+1.33 (+0.94%)

Check out this morning's…

ShowHide Related Items >><<
TTWO Take-Two
$213.30 /

+5.925 (+2.86%)

TLRY Tilray
$30.21 /

+4.51 (+17.55%)

SPGI S&P Global
$325.31 /

+1.315 (+0.41%)

KALV KalVista
$15.62 /

+0.41 (+2.70%)

INCY Incyte
$93.55 /

+3.27 (+3.62%)

IIVI II-VI
$88.69 /

+0.7 (+0.80%)

HTBX Heat Biologics
$8.37 /

+0.88 (+11.75%)

HBI Hanesbrands
$15.97 /

+0.11 (+0.69%)

GLUU Glu Mobile
$9.38 /

+0.19 (+2.07%)

FIS FIS
$133.39 /

+1.2 (+0.91%)

EKSO Ekso Bionics
$13.04 /

+2.59 (+24.78%)

EA Electronic Arts
$142.49 /

+1.33 (+0.94%)

COTY Coty
$7.95 /

+0.305 (+3.99%)

CNC Centene
$58.27 /

-0.525 (-0.89%)

CLF Cleveland-Cliffs
$17.33 /

+0.65 (+3.90%)

BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

ARMK Aramark
$37.02 /

+0.39 (+1.06%)

KALV KalVista
$15.62 /

+0.41 (+2.70%)

01/26/21 Needham
KalVista price target raised to $32 from $25 at Needham
12/10/20 Roth Capital
Roth Capital 'very bullish' on KalVista HAE Phase 2 data readout
10/15/20 Roth Capital
KalVista updates highlight potential to become HAE leader, says Roth Capital
06/15/20
Fly Intel: Top five analyst initiations
TLRY Tilray
$30.21 /

+4.51 (+17.55%)

02/02/21 Craig-Hallum
Legalization could drive '3x upside' for U.S. cannabis stocks, says Craig-Hallum
01/29/21 Stifel
'Goldilocks' scenario for U.S. cannabis industry in play, says Stifel
01/15/21 Alliance Global Partners
Aphria price target raised to C$20 from C$12 at Alliance Global Partners
01/15/21 BMO Capital
Aphria price target raised to C$15 from C$7 at BMO Capital
HTBX Heat Biologics
$8.37 /

+0.88 (+11.75%)

12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
10/14/20
Fly Intel: Top five analyst initiations
10/14/20 B. Riley
B. Riley sees 200% upside in 'value vaccine play' Heat Biologics
10/14/20 B. Riley
Heat Biologics initiated with a Buy at B. Riley Securities
SPGI S&P Global
$325.31 /

+1.315 (+0.41%)

01/14/21 BMO Capital
IHS Markit price target lowered to $93 from $99 at BMO Capital
12/04/20 Stifel
S&P Global upgraded to Buy from Hold at Stifel
12/02/20 Wells Fargo
Wells Fargo upgrades S&P Global ahead of IHS Markit combination
12/02/20 Wells Fargo
S&P Global upgraded to Overweight from Equal Weight at Wells Fargo
INCY Incyte
$93.55 /

+3.27 (+3.62%)

01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
11/06/20 RBC Capital
Incyte price target lowered to $86 from $96 at RBC Capital
ARMK Aramark
$37.02 /

+0.39 (+1.06%)

12/08/20 Barclays
Aramark price target raised to $40 from $35 at Barclays
11/18/20 RBC Capital
Aramark price target raised to $31 from $28 at RBC Capital
11/18/20 Barclays
Aramark price target raised to $35 from $25 at Barclays
10/22/20 Citi
Citi downgrades Aramark to Neutral with normalcy still year away
IIVI II-VI
$88.69 /

+0.7 (+0.80%)

02/08/21 JPMorgan
II-VI price target raised to $100 from $65 at JPMorgan
02/05/21 B. Riley
II-VI price target raised to $72 from $47 at B. Riley Securities
02/05/21 Deutsche Bank
II-VI price target raised to $100 from $63 at Deutsche Bank
02/04/21 Benchmark
II-VI price target raised to $105 from $85 at Benchmark
HBI Hanesbrands
$15.97 /

+0.11 (+0.69%)

01/21/21 Deutsche Bank
Hanesbrands price target raised to $16 from $14 at Deutsche Bank
12/14/20
Fly Intel: Top five analyst downgrades
12/14/20 Stifel
Hanesbrands downgraded to Hold from Buy at Stifel
09/24/20 B. Riley
B. Riley FBR highlights four apparel brands with little election risk
CNC Centene
$58.27 /

-0.525 (-0.89%)

01/21/21 Goldman Sachs
Centene initiated with a Neutral at Goldman Sachs
01/15/21
Fly Intel: Top five analyst downgrades
01/15/21 Jefferies
Magellan Health downgraded to Hold after takeover agreement at Jefferies
01/15/21 Jefferies
Jefferies downgrades Centene to Hold, sees Dem win benefits pulled forward
COTY Coty
$7.95 /

+0.305 (+3.99%)

12/07/20 Wells Fargo
Coty downgraded to Underweight from Equal Weight at Wells Fargo
11/19/20
Fly Intel: Top five analyst upgrades
11/19/20 Citi
Coty upgraded to Buy from Neutral at Citi
11/09/20 Deutsche Bank
Coty price target raised to $6 from $4 at Deutsche Bank
TTWO Take-Two
$213.30 /

+5.925 (+2.86%)

02/09/21 Wedbush
Take-Two price target raised to $226 from $210 at Wedbush
02/09/21 Cowen
Take-Two price target raised to $229 from $213 at Cowen
02/09/21 Credit Suisse
Take-Two price target raised to $204 from $199 at Credit Suisse
02/09/21 Barclays
Take-Two price target raised to $220 from $210 at Barclays
EKSO Ekso Bionics
$13.04 /

+2.59 (+24.78%)

06/26/20 H.C. Wainwright
Ekso Bionics price target raised to $12 from $8 at H.C. Wainwright
CLF Cleveland-Cliffs
$17.33 /

+0.65 (+3.90%)

02/03/21 Credit Suisse
U.S. Steel Industry upgraded to Overweight at Credit Suisse
01/26/21 GLJ Research
Cleveland-Cliffs downgraded to Hold on 'emerging headwinds' at GLJ Research
01/26/21 GLJ Research
Cleveland-Cliffs downgraded to Hold from Buy at GLJ Research
01/18/21 Exane BNP Paribas
Cleveland-Cliffs upgraded to Outperform from Neutral at Exane BNP Paribas
FIS FIS
$133.39 /

+1.2 (+0.91%)

02/03/21
Fly Intel: Top five analyst downgrades
02/03/21 Rosenblatt
FIS downgraded to Neutral from Buy at Rosenblatt
02/02/21 Oppenheimer
FIS price target lowered to $160 from $167 at Oppenheimer
02/01/21 BofA
US 1 List changes at BofA
BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

02/02/21 BTIG
Prothena upgraded to Buy at BTIG on birtamimab 'revival'
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
01/20/21 Citi
Citi opens 'negative Catalyst Watch' on Bristol-Myers
12/15/20 Goldman Sachs
Bristol-Myers upgraded to Conviction Buy from Buy at Goldman Sachs
GLUU Glu Mobile
$9.38 /

+0.19 (+2.07%)

02/09/21 KeyBanc
EA, Glu Mobile deal 'a smart strategic move,' says KeyBanc
02/09/21 Piper Sandler
Glu Mobile downgraded to Neutral from Overweight at Piper Sandler
02/09/21 Wedbush
Glu Mobile downgraded to Neutral from Outperform at Wedbush
02/09/21 DA Davidson
Glu Mobile downgraded to Neutral from Buy at DA Davidson
EA Electronic Arts
$142.49 /

+1.33 (+0.94%)

TTWO Take-Two
$213.30 /

+5.925 (+2.86%)

TLRY Tilray
$30.21 /

+4.51 (+17.55%)

SPGI S&P Global
$325.31 /

+1.315 (+0.41%)

KALV KalVista
$15.62 /

+0.41 (+2.70%)

INCY Incyte
$93.55 /

+3.27 (+3.62%)

IIVI II-VI
$88.69 /

+0.7 (+0.80%)

HTBX Heat Biologics
$8.37 /

+0.88 (+11.75%)

HBI Hanesbrands
$15.97 /

+0.11 (+0.69%)

GLUU Glu Mobile
$9.38 /

+0.19 (+2.07%)

FIS FIS
$133.39 /

+1.2 (+0.91%)

EA Electronic Arts
$142.49 /

+1.33 (+0.94%)

COTY Coty
$7.95 /

+0.305 (+3.99%)

CNC Centene
$58.27 /

-0.525 (-0.89%)

CLF Cleveland-Cliffs
$17.33 /

+0.65 (+3.90%)

BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

ARMK Aramark
$37.02 /

+0.39 (+1.06%)

  • 09
    Feb
  • 09
    Feb
  • 02
    Jul
  • 04
    Jun
TTWO Take-Two
$213.30 /

+5.925 (+2.86%)

TLRY Tilray
$30.21 /

+4.51 (+17.55%)

SPGI S&P Global
$325.31 /

+1.315 (+0.41%)

IIVI II-VI
$88.69 /

+0.7 (+0.80%)

HTBX Heat Biologics
$8.37 /

+0.88 (+11.75%)

GLUU Glu Mobile
$9.38 /

+0.19 (+2.07%)

FIS FIS
$133.39 /

+1.2 (+0.91%)

EA Electronic Arts
$142.49 /

+1.33 (+0.94%)

CNC Centene
$58.27 /

-0.525 (-0.89%)

CLF Cleveland-Cliffs
$17.33 /

+0.65 (+3.90%)

BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

TTWO Take-Two
$213.30 /

+5.925 (+2.86%)

TLRY Tilray
$30.21 /

+4.51 (+17.55%)

SPGI S&P Global
$325.31 /

+1.315 (+0.41%)

IIVI II-VI
$88.69 /

+0.7 (+0.80%)

HBI Hanesbrands
$15.97 /

+0.11 (+0.69%)

GLUU Glu Mobile
$9.38 /

+0.19 (+2.07%)

FIS FIS
$133.39 /

+1.2 (+0.91%)

EA Electronic Arts
$142.49 /

+1.33 (+0.94%)

COTY Coty
$7.95 /

+0.305 (+3.99%)

CNC Centene
$58.27 /

-0.525 (-0.89%)

CLF Cleveland-Cliffs
$17.33 /

+0.65 (+3.90%)

BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

ARMK Aramark
$37.02 /

+0.39 (+1.06%)

TTWO Take-Two
$213.30 /

+5.925 (+2.86%)

TLRY Tilray
$30.21 /

+4.51 (+17.55%)

SPGI S&P Global
$325.31 /

+1.315 (+0.41%)

KALV KalVista
$15.62 /

+0.41 (+2.70%)

INCY Incyte
$93.55 /

+3.27 (+3.62%)

HTBX Heat Biologics
$8.37 /

+0.88 (+11.75%)

HBI Hanesbrands
$15.97 /

+0.11 (+0.69%)

GLUU Glu Mobile
$9.38 /

+0.19 (+2.07%)

FIS FIS
$133.39 /

+1.2 (+0.91%)

EKSO Ekso Bionics
$13.04 /

+2.59 (+24.78%)

EA Electronic Arts
$142.49 /

+1.33 (+0.94%)

COTY Coty
$7.95 /

+0.305 (+3.99%)

CNC Centene
$58.27 /

-0.525 (-0.89%)

CLF Cleveland-Cliffs
$17.33 /

+0.65 (+3.90%)

BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

ARMK Aramark
$37.02 /

+0.39 (+1.06%)

Hot Stocks
Heat Biologics reports interim data from HS-110 combination trial » 07:38
02/09/21
02/09
07:38
02/09/21
07:38
HTBX

Heat Biologics

$8.37 /

+0.88 (+11.75%)

, BMY

Bristol-Myers

$60.24 /

-0.67 (-1.10%)

Heat Biologics (HTBX)…

Heat Biologics (HTBX) reported interim data of the company's fully-enrolled Phase 2 trial of HS-110, in combination with Bristol-Myers' (BMY) Opdivo in advanced non-small cell lung cancer, or NSCLC. HS-110 is an "off-the-shelf" allogeneic cell-based therapy designed to activate patients' immune system against multiple cancer testis antigens to elicit a diverse and robust immune response against tumor cells. Substantial survival benefit was observed in a cohort of previously treated, checkpoint inhibitor naive patients with advanced NSCLC. A median progression free survival, or PFS, of 1.8 months and a median overall survival, or OS, of 24.6 months was observed with a median follow-up time of 19.4 months. The one-year survival rate of Cohort A is 61.7%. The median OS data was 12.2 months and the one-year survival rate was 50.7% in previously treated, advanced NSCLC patients who received nivolumab as a single agent, according to published data of the BMS CheckMate 057 study. Our data suggests that addition of HS-110 to a checkpoint inhibitor has the potential to improve survival benefit for checkpoint inhibitor naive NSCLC patients. For NSCLC patients who had previously been treated with a checkpoint inhibitor and whose disease had subsequently progressed, a median PFS of 2.8 months and median OS of 11.9 months was observed with a median follow-up time of 11.9 months. NSCLC patients whose disease progresses following checkpoint inhibitor therapy have limited treatment options. Published data from other studies reported median OS of 6.8 to 9.0 months for NSCLC patients treated with chemotherapies after PD-L1 progression. Data of HS-110 in combination with nivolumab in Cohort B suggests potential treatment benefit for NSCLC patients whose disease progressed following treatment with PD-L1 therapy. As of this data cut, 30% of the patients in Cohort A and 26% of the patients in Cohort B are still alive. HS-110 has a favorable safety profile and has been administered in approximately 200 patients to date. As of this data cut, there have been no treatment-related serious adverse reactions. A review of immune-related adverse events reported in the study raised no safety concerns. The data to date demonstrate that combination of HS-110 and nivolumab is well-tolerated.

ShowHide Related Items >><<
HTBX Heat Biologics
$8.37 /

+0.88 (+11.75%)

BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

HTBX Heat Biologics
$8.37 /

+0.88 (+11.75%)

12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
10/14/20
Fly Intel: Top five analyst initiations
10/14/20 B. Riley
B. Riley sees 200% upside in 'value vaccine play' Heat Biologics
10/14/20 B. Riley
Heat Biologics initiated with a Buy at B. Riley Securities
BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

02/02/21 BTIG
Prothena upgraded to Buy at BTIG on birtamimab 'revival'
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
01/20/21 Citi
Citi opens 'negative Catalyst Watch' on Bristol-Myers
12/15/20 Goldman Sachs
Bristol-Myers upgraded to Conviction Buy from Buy at Goldman Sachs
HTBX Heat Biologics
$8.37 /

+0.88 (+11.75%)

BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

HTBX Heat Biologics
$8.37 /

+0.88 (+11.75%)

BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

HTBX Heat Biologics
$8.37 /

+0.88 (+11.75%)

BMY Bristol-Myers
$60.24 /

-0.67 (-1.10%)

Options
One new option listing on January 29th » 08:30
01/29/21
01/29
08:30
01/29/21
08:30
HTBX

Heat Biologics

$7.11 /

-0.25 (-3.40%)

New option listings for…

New option listings for January 29th include Heat Biologics (HTBX).

ShowHide Related Items >><<
HTBX Heat Biologics
$7.11 /

-0.25 (-3.40%)

HTBX Heat Biologics
$7.11 /

-0.25 (-3.40%)

12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
10/14/20
Fly Intel: Top five analyst initiations
10/14/20 B. Riley
B. Riley sees 200% upside in 'value vaccine play' Heat Biologics
10/14/20 B. Riley
Heat Biologics initiated with a Buy at B. Riley Securities
HTBX Heat Biologics
$7.11 /

-0.25 (-3.40%)

HTBX Heat Biologics
$7.11 /

-0.25 (-3.40%)

Hot Stocks
Heat Biologics announces publication of preclinical COVID-19 results » 07:51
01/27/21
01/27
07:51
01/27/21
07:51
HTBX

Heat Biologics

$8.74 /

+0.71 (+8.84%)

Heat Biologics announced…

Heat Biologics announced the publication of additional preclinical COVID-19 results in Frontiers in Immunology, a peer reviewed journal, which is available online. The publication highlights additional data sets around memory T-cells that builds upon data previously reported and published in bioRxiv. Specifically, the new data demonstrates polyfunctional, anti-viral cytokine releasing, Spike protein specific CD8+ and CD4+ T-cell memory responses in the lungs and spleen of immunized animals, observed 30 days post single vaccination. Additionally, memory CD8+ T-cell responses were observed 60 days post vaccination in the lungs of mice. The new data points to the significance of lung tissue-resident memory T-cells which are required for clearance of respiratory virus infections. Vaccination strategies that target generation of tissue-resident memory T-cells and their persistence may provide enhanced immunity compared with vaccines that rely on circulating responses.

ShowHide Related Items >><<
HTBX Heat Biologics
$8.74 /

+0.71 (+8.84%)

HTBX Heat Biologics
$8.74 /

+0.71 (+8.84%)

12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
10/14/20
Fly Intel: Top five analyst initiations
10/14/20 B. Riley
B. Riley sees 200% upside in 'value vaccine play' Heat Biologics
10/14/20 B. Riley
Heat Biologics initiated with a Buy at B. Riley Securities
HTBX Heat Biologics
$8.74 /

+0.71 (+8.84%)

HTBX Heat Biologics
$8.74 /

+0.71 (+8.84%)

Hot Stocks
Heat Biologics commences manufacturing process for ZVX-60 » 07:37
01/19/21
01/19
07:37
01/19/21
07:37
HTBX

Heat Biologics

$6.36 /

+0.15 (+2.42%)

Heat Biologics announces…

Heat Biologics announces it has transferred its gp96-based COVID-19 vaccine cell line to Waisman Biomanufacturing to initiate the manufacturing process for ZVX-60, which is being developed for use as either a standalone vaccine, or in combination with other vaccines, to enhance prophylactic protection against COVID-19.

ShowHide Related Items >><<
HTBX Heat Biologics
$6.36 /

+0.15 (+2.42%)

HTBX Heat Biologics
$6.36 /

+0.15 (+2.42%)

12/24/20 B. Riley
Heat Biologics transferred with a Buy at B. Riley Securities
10/14/20
Fly Intel: Top five analyst initiations
10/14/20 B. Riley
B. Riley sees 200% upside in 'value vaccine play' Heat Biologics
10/14/20 B. Riley
Heat Biologics initiated with a Buy at B. Riley Securities
HTBX Heat Biologics
$6.36 /

+0.15 (+2.42%)

HTBX Heat Biologics
$6.36 /

+0.15 (+2.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.